AI-generated from publicly available materials.Broken String Biosciences has introduced BaseMap ABE, a novel tool designed to enhance the characterization of off-target effects in adenine base editing (ABE) applications.
This launch comes as base editing is increasingly recognized for its ability to facilitate precise genomic alterations. As ABE technologies gain traction in therapeutic settings, there is a growing need for reliable methods to identify and characterize unintended off-target modifications. According to Terry Pizzie, the CEO of Broken String Biosciences, existing prediction-based methods fall short, prompting the need for a more comprehensive approach.
BaseMap ABE distinguishes itself by generating genome-wide data from biologically relevant cells, allowing for a clearer assessment of editing specificity under conditions that mimic physiological environments. This platform not only accelerates the identification of off-target events but also produces standardized data that can guide the optimization of editing tools and inform preclinical decisions.
As part of its initial rollout, Broken String Biosciences is launching an Early Access Program to collaborate with researchers engaged in the development of genome editing therapies. This initiative aims to gather user feedback to refine the platform further, highlighting the company's commitment to advancing base editing technologies in a clinically relevant manner.